Bio/Pharma News

Catalent and MGC Pharma Partner for Production of Cell Lines

January 20, 2015

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Boehringer Ingelheim Partners with Vanderbilt University to Develop Ras Inhibitors

January 15, 2015

Boehringer Ingelheim announced that it would partner with Vanderbilt University to research and develop Ras inhibitors for the treatment of cancers affected by Ras mutation.

Sanofi Forms Strategic Pact with Boehringer Ingelheim for Biologics Manufacture

January 15, 2015

Sanofi has entered into a strategic manufacturing collaboration with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies (mAbs).

Catalent and Sanofi to Collaborate on ADC Development

January 15, 2015

Catalent Pharma Solutions and Sanofi-Aventis R&D have entered into a collaboration to develop Sanofi’s proprietary antibodies using Catalent’s SMARTag antibody drug conjugate (ADC) platform.

EFPIA and IMI Announce New Projects to Fight Ebola

January 15, 2015

Eight new projects will focus on the diverse needs of the Ebola epidemic, such as new vaccine development, production and distribution, and new diagnostic methods.

Shire Acquires NPS Pharma for $5.2 billion

January 12, 2015

Shire adds rare-disease portfolio with acquisition of NPS Pharma.

Bristol-Myers Squibb Celebrates Superior Overall Survival for Opdivo

January 12, 2015

Bristol-Myers Squibb announced that it stopped its study of Opdivo for the treatment of 2nd line squamous cell lung cancer due to superior overall survival of study participants.

Argos and Saint-Gobain Partner on Single-Use Components for Immunotherapy Manufacturing

January 09, 2015

Single-use components aid efficiency in automated personalized therapy manufacturing.

Cardio3 BioSciences Acquires OnCyte CAR T-Cell Portfolio for $180 million

January 07, 2015

Cardio3 BioSciences acquired Celdara Medical’s immuno-oncology platform, OnCyte, for up to $180 million in cash, stock, and royalties.

CVS Health Announces Hepatitis C Drug Exclusivity Deal with Gilead

January 06, 2015

The exclusivity deal mirrors that of the recent deal between Express Scripts and AbbVie for Viekira Pak.